Thiopurine-induced pancreatitis in leading Crohn’s disease guideline publications
| Guideline | Reference to pancreatitis | Quantification of thiopurine-association pancreatitis risk |
| British Society of Gastroenterology consensus guidelines21
Published June 2019 | Recognises that thiopurines are contraindicated in pancreatitis, even at a low dose, due to high chances for recurrence. Does not state risk of occurrence on thiopurines. | No effect size estimate provided. |
| National Institute for Health and Care Excellence—NG12922
Published May 2019 | Recognises that thiopurines are contraindicated if a patient has experienced past episodes of pancreatitis. Does not state risk of occurrence on thiopurines. | No effect size estimate provided. |
| American College of Gastroenterology clinical guideline23
Published April 2018 | Recognises that thiopurines are associated with pancreatitis. | No effect size estimate provided. |
| Japanese Society of Gastroenterology clinical practice guidelines24
Published February 2018 | Recognised pancreatitis as a side effect of azathioprine and 6-mercaptopurine (evidence level: A) | No effect size estimate provided. |
| European Crohn’s and Colitis Organisation consensus guideline25 26
Published September 2016 | Recognises that thiopurines are contraindicated if a patient has previous experienced episodes of pancreatitis. Does not state risk of occurrence on thiopurines. | No effect size estimate provided. |
| World Gastroenterology Organisation global guidelines27
Published August 2015 | No reference. | No effect size estimate provided. |
| American Gastroenterological Association Institute guideline28
Published December 2013 | No reference. | No effect size estimate provided. |